Thermo Fisher Collaborates on Major Proteomics Biobank Initiative in Singapore's PRECISE-SG100K Project

- Thermo Fisher Scientific collaborates with PRECISE to establish a large-scale proteomics biobank initiative in Singapore.
- The partnership supports the PRECISE-SG100K project, one of Asia's largest population health studies.
- Thermo Fisher will employ advanced technology to enhance health research and personalized medicine development.
Thermo Fisher Scientific (NYSE:TMO) announces a strategic collaboration with Precision Health Research, Singapore (PRECISE), aimed at significantly enhancing health research capabilities in the region. This partnership develops the PRECISE-SG100K project, recognized as one of Asia's extensive longitudinal population health studies, focusing on proteomics data collection and analysis.
Revolutionizing Population Health Research
Through this collaboration, Thermo Fisher intends to deploy its advanced platforms, including the Olink PEA and the Orbitrap Astral mass spectrometry system. The initiative's primary goal is to forge a regulatory-grade biobank infrastructure that supports large-scale health research. This infrastructure is expected to play a pivotal role in bolstering scientific inquiry surrounding population health and advancing personalized medicine strategies in Singapore and beyond.
Focus on Proteomics and Personalized Medicine
By integrating complementary technologies in proteomics, Thermo Fisher aims not only to enhance research capacity but also to facilitate better understanding of health outcomes across diverse populations. This strategic move aligns with global trends toward precision health measures that cater to individual needs, promising to transform how health sciences address the unique health challenges faced by populations.
Commitment to Advancing Health Solutions
This collaboration highlights Thermo Fisher's commitment to being at the forefront of innovation in life sciences. As the project progresses, it anticipates nurturing a collaborative environment between researchers and healthcare professionals, thereby enhancing the delivery of tailored health solutions that could lead to significant advancements in public health initiatives.
In summary, Thermo Fisher Scientific's partnership with PRECISE marks a significant step forward in large-scale health research, setting a foundation for future innovations in personalized medicine through robust proteomics initiatives.